CA-CREATIVE-ARTISTS
17.4.2017 20:06:17 CEST | Business Wire | Press release
Creative Artists Agency (CAA), the world’s leading entertainment and sports agency, has partnered with CMC Capital Partners (CMC), China’s leading investment fund in media and entertainment, Internet and mobile, and lifestyle. The robust partnership includes the formation of CAA China, a world-class media and entertainment platform, and a minority strategic investment by CMC in CAA. Creating alignment throughout the agency, CMC Chairman Li Ruigang will join CAA’s Board of Directors.
Majority-owned by CAA, CAA China combines the expertise and vast resources of CAA with the broad reach and network of CMC in Greater China. CMC’s tremendous market experience in entertainment and sports combined with CAA’s representation of top Chinese talent, in addition to its leadership in film finance, will create a wide spectrum of new business and client opportunities in the swiftly growing Chinese market, ranging from talent representation, endorsements, and sports, to digital media, music, and original content production.
With more than two dozen employees in Beijing, CAA opened its China office in 2005 and has successfully built out its multiplatform approach to the market. The company has been at the center of every major Chinese co-production for the past 10 years and has packaged, sold, or raised financing for more than 75 Chinese-language film projects. CAA's Global Film Finance & Sales Group has directed more than $400 million in Chinese capital into English-language content. In addition, under the leadership of Jonah Greenberg, who runs the agency’s China efforts in motion pictures, CAA represents many of the most accomplished actors, directors, writers, and producers from Mainland China, Taiwan and Hong Kong, including Zhang Yimou, Lin Chi-ling, and Donnie Yen, among others.
“For more than a decade, we have served as a vital bridge to and within the Chinese market, utilizing our deep experience and network to support the work of the region’s best artists and to develop opportunities within the market for international talent,” said CAA President Richard Lovett. “CAA China will supercharge our efforts, from motion pictures, television, endorsements, and brand consulting to sports, live events, digital media, and beyond. CMC, under the leadership of Li Ruigang, has a remarkable record of success in the region, and we are confident that our partnership will yield tremendous results for our clients and future business partners in China.”
“We believe China and the US are the two biggest entertainment markets and play pivotal roles on the global landscape. The partnership not only creates commercial and industry value, but also serves as an innovative force in the evolution of the Chinese media industry,” said CMC Chairman Li Ruigang. “CAA is a prominent institution in the US entertainment and sports sector, which has built its success on systematically and consistently enabling the success of their clients throughout the years. We are immensely excited about the potential possibilities of an enhanced China angle by CMC coupled with the experience and resources of CAA. CMC has been in a highly productive cooperation with CAA under the leadership of Richard Lovett, and we look forward to greater accomplishments in the future.”
Founded by Li in 2010, CMC is a leading investor in media and entertainment, Internet and mobile, and lifestyle sectors in China. With a deep understanding of the China market, an extensive network of industry resources and prominent operational capabilities, CMC has invested and operated in Greater China, North America, Europe and Asian markets, and has created and supported the growth of many champions and emerging leaders in film, television, animation, kids content, sports, music, fashion, games, location-based entertainment, cinema, digital media, social platform, and entertainment technology. CMC’s previous and current investment and operational portfolio includes IMAX China; Star China, China’s top variety production company; Flagship, a joint venture studio with Warner Bros.; and City Football Group, a football club management company that owns Manchester City Football Club and New York City Football Club. Prior to founding CMC, Li was the Chairman and CEO of Shanghai Media Group (SMG) for more than ten years and successfully transformed SMG from a provincial broadcaster into a leading media conglomerate in China.
“CAA China demonstrates the vision and innovation that has driven CAA’s growth and fueled its ability to stay on the leading edge of industry trends,” said Jim Coulter, co-founder of private equity firm TPG, CAA’s majority shareholder. “CAA has had a significant impact on the Chinese entertainment marketplace by enabling its clients’ success over the past 12 years. We are thrilled with the company’s progress and the value-creation CAA has realized for its shareholders since our investment. With CMC as a meaningfully invested partner, and continuing growth in the Chinese market, the potential for CAA China is limitless.”
Greenberg will continue to lead CAA’s China efforts in motion pictures, working with the existing team in the Beijing office. Roeg Sutherland, Co-Head of CAA’s Global Film Finance and Sales Group, will continue to lead the agency’s film finance business in the market. CAA China will progressively add additional senior management to help expand the business into new entertainment and sports areas.
About Creative Artists Agency
Leading entertainment and sports agency Creative Artists Agency (CAA) represents many of the most successful professionals working in film, television, music, theatre, video games, sports, and digital content, and provides a range of strategic marketing and consulting services to corporate clients. CAA is also a leader in sports, representing more than 1,000 of the world’s top athletes in football, baseball, basketball, hockey, soccer, tennis, Olympics and action sports, and golf, and works in the areas of broadcast rights, corporate marketing initiatives, licensing, and sports properties for sales and sponsorship opportunities.
About CMC
CMC, founded and chaired by Li Ruigang, is China's leading investment and operating platform in media & entertainment, Internet & mobile, and lifestyle, and invests and operates in Greater China, north America, Europe and Asian markets. With a deep understanding of the China market, an extensive network of industry resources and prominent operational capabilities, CMC has created and supported the growth of many industry leaders in subsectors including film, television, animation, sports, music, fashion, games, advertising, marketing, financial media, location-based entertainment, cinema, online video platforms, OTT, smart TV and social media.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170417005739/en/
Contact:
Creative Artists Agency
424.288.2000
Michael Mand, Mmand@caa.com
Beth
McClinton, Beth.McClinton@caa.com
Missy
Davy, Mdavy@caa.com
or
CMC
Jiaming
Wu, Jiaming.Wu@cmccap.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
